Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Thomas Grace, MD
Advertisement
Articles by Thomas Grace, MD
Advertisement
Latest Updated Articles
Combined Effect of Continuous Glucose Monitoring and Semaglutide: Analysis of Administrative ClaimsPublished: April 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
2
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
3
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
4
Looking at Respiratory Health Through a Global Lens at ERS 2025
5
